Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Godavari Drugs Ltd

    Godavari Drugs Limited is in the business of Contract Manufacturing, Loan License Manufacturing, Manufacturing and Supply of API, drug intermediaries and fine chemicals, capable

  • No Image

    Concord Drugs Ltd is a public limited company established in 1995, is among the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulat

  • No Image
    Granules India Ltd

    Granules India Limited. A fast growing global pharmaceutical company. World-class facilities for APIs, PFIs and Finished Dosages. Serving customers in over 60 countries. Committ